PMED.OB

[doyerdiligence]

Parlay those pmed profits

[higherstocks]

PMED looks good at .005  Ill wait till then

[gri64]

We have a news and  +32%

http://biz.yahoo.com/bw/060619/20060619005854.html?.v=1

I can't understand this news - does it promise a real profit in the future? 
I'm in @0.0085 - I see It's very, very risky, but .... 

Any opinion will be appreciated.

[SarfiSoy]

1.2bil SB-2 on this puppy. Reminds me of GZFX unfortunately, although more promising. Not bashing, just risky, very risky imo.

[doyerdiligence]

they won't dilute that much, the SB-2 share structure will fluctuate greatly depending on the PPS. Just call the transfer agent on the regular to get an updated count, if you fear dilution that much.  but fears this will be like GZFX are unfounded, it would first need to make a nice run like GZFX did before they would dilute it into oblivion. This is still yet to run and looking at the moving lines that have been playing resistance all year, once they are broke it should make a nice little run regardless of this Sb-2. I've seen countless stocks run with s8/sb-2 out.

[higherstocks]

they won't dilute that much, the SB-2 share structure will fluctuate greatly depending on the PPS. Just call the transfer agent on the regular to get an updated count, if you fear dilution that much.  but fears this will be like GZFX are unfounded, it would first need to make a nice run like GZFX did before they would dilute it into oblivion. This is still yet to run and looking at the moving lines that have been playing resistance all year, once they are broke it should make a nice little run regardless of this Sb-2. I've seen countless stocks run with s8/sb-2 out.

LMAO

[doyerdiligence]

Press Release   Source: Paradigm Medical Industries, Inc.

Paradigm Medical Industries to Introduce Several New Instruments at AAO Convention
Wednesday October 4, 9:51 am ET

SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED/PMEDW), a leading innovative producer of ultrasound devices for the ophthalmic and medical industries, disclosed today it has finalized an agreement with Tinsley, a division of Hartest Precision Instruments, Ltd. (Croydon, UK), whereby the latter will construct a new-generation compact Visual Field Screener (VFS) Perimeter on behalf and for Paradigm Medical. The new LD700 Perimeter measures visual field loss caused by glaucoma, head trauma, or other neurological disorders that can impact the visual pathways. It will be marketed by Paradigm Medical on a global scale.

ADVERTISEMENT
Paradigm Medical's Dicon(TM) Perimeters already are a standard of care in the protection and monitoring of glaucoma worldwide.

"The LD700 will be our third-generation perimeter," noted Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "It already has received U.S. Food & Drug Administration and European CE Mark regulatory approval. We will introduce this new, state-of-the-art device at the American Academy of Ophthalmology (AAO) Convention next month in Las Vegas."

Paradigm Medical reported it will also be launching domestically several other sophisticated ultrasound devices and instruments at AAO, some of which have been developed via its agreement with MEDA Corp., one of China's leading developers and producers of ultrasound devices. That agreement was completed in June 2006. Paradigm Medical is already selling some of these devices in international markets, where customer response has been very positive.

The new instruments include an Ultrasound A-Scan (which is used to measure axial length of the eye), a Pachymeter (which is used for measuring corneal thickness), an A-Scan/Pachymeter (which is a combination of the two stand-alone devices), and two A/B Scans (one is an ultrasound imaging device for detecting abnormalities within the eye; the second is designed to provide portability for ophthalmology veterinary applications).

"We are unaware of any other company that has introduced so many ophthalmic devices/instruments at any one time within the industry," Mr. Cannefax said. "It represents further validation of our strategy to upgrade the Company's product offerings and broaden the global market opportunity for sophisticated, high-tech, high-value-added instrumentation for the detection, treatment and management of ophthalmic disease.

"We believe our expanded portfolio should provide our customers, suppliers, competitors and employees with evidence that Paradigm Medical is making significant progress in repositioning itself as a strong force in the global ophthalmic market. We have also shown that we can work with other industry leaders in creating next-generation instrumentation to combat eye disease," Mr. Cannefax added.

Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed "The UBM Company" (Ultrasound BioMicroscope). Contact us at 801-977-8970 or visit us at www.paradigm-medical.com.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.


Contact:

Paradigm Medical Industries, Inc.
Raymond Cannefax, 801-977-8970

Source: Paradigm Medical Industries, Inc.

[hottea]

Paradigm Medical Receives FDA Approval for New-Generation Ultrasound Devices
Wednesday February 7, 9:04 am ET
Collaboration with China's MEDA results in development of new array of devices ready to meet global market needs


SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB), a leading innovative producer of ultrasound devices for the ophthalmic and medical industries, disclosed today it has received U.S. Food and Drug Administration (FDA) approval to market a new generation of Ultrasound devices. The products were developed through a collaboration with MEDA Co. Ltd., one of China's leading developers and manufacturers of ultrasound devices. The collaboration was formed in June 2006.
ADVERTISEMENT


The new devices were unveiled at the recent American Academy of Ophthalmology (AAO) Convention, and have already received orders internationally.

"The FDA's approval of our 510(k) application will result in an immediate, stepped-up marketing campaign in the U.S. and Canada," said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "The Company has already built inventories based on strong international demand and anticipated U.S. regulatory approval."

The new devices include the P2000 A-Scan (used to measure axial length of the eye); P2200 Pachymeter (used for measuring corneal thickness); P2500 A-Scan/Pachymeter (a combination of the two stand-alone devices); P2700 AB/Scan (an ultrasound imaging device for detecting abnormalities within the eye); and P37-II (a more advanced AB/Scan used to provide portability for ophthalmology veterinary applications). "We believe the P37-II will set the new gold standard for AB/Scan in the industry," Mr. Cannefax noted.

"FDA approval for use of these devices and the recent operations management reorganization we implemented at the beginning of this year will have a favorable effect on our performance in 2007 and beyond," Mr. Cannefax added. "The Company clearly has become one of the leading, multi-product Ultrasound device producers in the world."

Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed "The UBM Company" (Ultrasound BioMicroscope). Contact us at 801-977-8900 or visit us at www.paradigm-medical.com.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

[hottea]

day traders must be all over this one.

[runner2847]

Any thoughts on where this one heads from here? The news sounds pretty legit and its what I and a number of other people were wating on last spring when the rumors first started coming out that they would get some kind of a deal in China.

Is it above a penny from now on or is this going back down when the day traders are done?

[hottea]

Any thoughts on where this one heads from here? The news sounds pretty legit and its what I and a number of other people were wating on last spring when the rumors first started coming out that they would get some kind of a deal in China.

Is it above a penny from now on or is this going back down when the day traders are done?

Must be nice the news you been waiting for so long finally came out. 

Volume went way down, doesn't look like too many people were selling their shares.  I think a penny is pretty safe for now, I wish I bought some at a penny this morning when I had the chance.

Trying to figure out how much this is worth.

[runner2847]

Let me know what you come up with on that. Over on another board people seem optimistic that this news means the company is legit now and will start making some money. If that is the case it seems like this could be a multi bagger from here.

[nullzero]

I dont care how good the news is. When something runs up +500% in one day its way to risky. Im staying away, people from earlier this morning can dump big time at the EOD or tomorrow to get their 500% profits.

[runner2847]

Yeah a big pull back wouldnt be a surprise at this point. One post I read said that at .03 the company's market cap is 6mi. I dont know if thats correct or not based on the number of outstanding shares. With the FDA approval and sales in China, it seems like the company would be worth well in excess of that now.

thoughts?

[hottea]

If I had gotten in early this morning, I would sell enough to minimize my risk.
Pretty sure people would take profits too, but hard to say when.  There are still lots of buying at the moment.